MedTrace Logo

Postpartum Uterotonic Administration

NCT02495272 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2015-07-13

No results posted yet for this study

Summary

The investigators are planning to determine the effect of the timing of oxytocin administration on the amount of blood loss, necessity for additional medical or surgical interventions.

Conditions

  • Postpartum Bleeding

Interventions

DRUG

Oxytocin

Oxytocin 10IU Administered intramuscularly.

Sponsors & Collaborators

  • Kanuni Sultan Suleyman Training and Research Hospital

    collaborator OTHER

  • Bagcilar Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Burak Ozkose, MD · Kanuni Sultan Suleyman Teaching and Research Hospital, Istanbul

  • Dogukan Yildirim, MD · Kanuni Sultan Suleyman Teaching and Research Hospital, Istanbul

  • Eser S Ozyurek, MD · Bagcilar Training and Research Hospital

  • Batuhan Ustun, MD · Kanuni Sultan Suleyman Teaching and Research Hospital, Istanbul

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-12-31
Completion
2016-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02495272 on ClinicalTrials.gov